Immediate Impact
16 standout
Citing Papers
Targeting the STAT3/IL-36G signaling pathway can be a promising approach to treat rosacea
2024 Standout
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
2024 Standout
Works of Shuni Ying being referenced
The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside
2020
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Shuni Ying | 109 | 43 | 33 | 141 | 54 | 14 | 261 | |
| Kenshiro Tsuda | 67 | 30 | 35 | 105 | 49 | 14 | 256 | |
| Helena Iznardo | 126 | 46 | 24 | 156 | 28 | 17 | 278 | |
| Sairah Khan | 83 | 53 | 34 | 106 | 29 | 17 | 266 | |
| Masaru Karakawa | 137 | 31 | 20 | 222 | 34 | 14 | 279 | |
| Akmal S. Hassan | 157 | 28 | 18 | 165 | 27 | 17 | 304 | |
| Giuseppe Fabrizio Amoruso | 99 | 37 | 13 | 133 | 33 | 15 | 269 | |
| Karl M. Hoegler | 101 | 27 | 11 | 112 | 32 | 15 | 224 | |
| Julianty Angsana | 69 | 30 | 20 | 167 | 48 | 11 | 292 | |
| Mark Anliker | 140 | 29 | 18 | 63 | 27 | 16 | 280 | |
| Yavuz Harmanyeri | 75 | 80 | 17 | 88 | 25 | 17 | 245 |
All Works
Login with ORCID to disown or claim papers
Loading papers...